Alexion Pharmaceuticals was founded in 1992 and is headquartered in New Haven, US

Alexion Pharmaceuticals has offices in New Haven, Zürich, Barcelona, London and in 26 other locations

New Haven, US (HQ)

100 College St

Zürich, CH

30 Giesshübelstrasse

Alexion Pharmaceuticals's revenue was reported to be $870 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 870 m |

## Gross profit (Q1, 2017) | 801 m |

## Gross profit margin (Q1, 2017), % | 92% |

## Net income (Q1, 2017) | 170 m |

## EBIT (Q1, 2017) | 212 m |

## Market capitalization (15-Aug-2017) | 30.4 b |

## Cash (31-Mar-2017) | 713 m |

Alexion Pharmaceuticals's current market capitalization is $30.4 b.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 1.6 b | 2.2 b | 2.6 b | 3.1 b |

## Revenue growth, % | 44% | 17% | 18% | |

## Cost of goods sold | 233.1 m | 258 m | ||

## Gross profit | 1.4 b | 2.1 b | 2.4 b | 2.8 b |

## Gross profit Margin, % | 89% | 92% | 91% | 92% |

## R&D expense | 757 m | |||

## General and administrative expense | 954 m | |||

## Operating expense total | 845.8 m | 1.2 b | 1.8 b | 2.2 b |

## EBIT | 528 m | 868.7 m | 536.7 m | 667 m |

## EBIT margin, % | 34% | 39% | 21% | 22% |

## Interest expense | 47.7 m | 97 m | ||

## Pre tax profit | 498.1 m | 576 m | ||

## Income tax expense | 353.8 m | 177 m | ||

## Net Income | 252.9 m | 656.9 m | 144.4 m | 399 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 636.2 m | 666.6 m | 701 m | 753.1 m | 799.1 m | 870 m | |||

## Cost of goods sold | 39.6 m | 51.9 m | 69.4 m | 52 m | 54.1 m | 59 m | 60.6 m | 71.1 m | 69 m |

## Gross profit | 584.2 m | 612.6 m | 642.1 m | 692.5 m | 728 m | 801 m | |||

## Gross profit Margin, % | 92% | 92% | 92% | 92% | 91% | 92% | |||

## R&D expense | 92.6 m | 100.7 m | 221.1 m | 131.7 m | 165.7 m | 176.3 m | 179.3 m | 195.7 m | 219 m |

## General and administrative expense | 159.5 m | 157.7 m | 187.1 m | 221.4 m | 212.5 m | 232.6 m | 231.8 m | 230.1 m | 262 m |

## Operating expense total | 252 m | 258.3 m | 408.2 m | 353.1 m | 378.2 m | 408.9 m | 411.1 m | 425.8 m | 481 m |

## EBIT | 218.8 m | 236.7 m | 103.7 m | 181.1 m | 154.6 m | 165.8 m | 194.7 m | 179.3 m | 212 m |

## EBIT margin, % | 28% | 23% | 24% | 26% | 22% | 24% | |||

## Interest expense | (715 k) | (655 k) | (651 k) | (4 m) | (20 m) | (23.9 m) | (23.8 m) | (24.8 m) | (24 m) |

## Pre tax profit | 218.6 m | 236.2 m | 106.9 m | 177.3 m | 139.4 m | 143.6 m | 170 m | 158.1 m | 194 m |

## Income tax expense | 52.2 m | 58.5 m | 15.6 m | 7.1 m | 323.1 m | 51.4 m | 55 m | 63.8 m | 24 m |

## Net Income | 166.5 m | 177.7 m | 91.3 m | 170.2 m | (183.8 m) | 92.2 m | 114.9 m | 94.3 m | 170 m |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 529.9 m | 944 m | 1 b | 966 m |

## Accounts Receivable | 650 m | |||

## Inventories | 102.6 m | 176.4 m | 289.9 m | 375 m |

## Current Assets | 2.2 b | 2.8 b | 2.4 b | 2.6 b |

## PP&E | 201.1 m | 392.2 m | 697 m | 1 b |

## Goodwill | 254.1 m | 254.1 m | 5 b | 5 b |

## Total Assets | 3.3 b | 4.2 b | 13.1 b | 13.3 b |

## Accounts Payable | 21.6 m | 44 m | 57.4 m | 64 m |

## Total Debt | 167 m | |||

## Current Liabilities | 582.4 m | 606.7 m | 718.3 m | 823 m |

## Total Liabilities | 4.6 b | |||

## Additional Paid-in Capital | 2.1 b | 2.6 b | 7.7 b | 8 b |

## Retained Earnings | 379.1 m | 1 b | 1.2 b | 1.8 b |

## Total Equity | 2.4 b | 3.3 b | 8.3 b | 8.7 b |

## Debt to Equity Ratio | 0 x | |||

## Debt to Assets Ratio | 0 x | |||

## Financial Leverage | 1.4 x | 1.3 x | 1.6 x | 1.5 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 612 m | 752.2 m | 916.8 m | 1.3 b | 1.2 b | 710.2 m | 597.6 m | 762 m | 713 m |

## Accounts Receivable | 440.7 m | 436.5 m | 479.9 m | 535.8 m | 512.3 m | 586.2 m | 609.3 m | 676.8 m | 660 m |

## Inventories | 144.9 m | 140 m | 174.5 m | 234.3 m | 236.5 m | 294 m | 329.8 m | 363.1 m | 396 m |

## Current Assets | 2.3 b | 2.6 b | 2.9 b | 2.5 b | 2.5 b | 2.1 b | 2.4 b | 2.6 b | 2.7 b |

## PP&E | 273.3 m | 328.5 m | 440.5 m | 555.4 m | 618.7 m | 749.3 m | 825.3 m | 931.1 m | 1.1 b |

## Goodwill | 254.1 m | 254.1 m | 254.1 m | 5 b | 5 b | 5 b | 5 b | 5 b | 5 b |

## Total Assets | 3.6 b | 3.9 b | 4.4 b | 13.2 b | 13.2 b | 12.8 b | 13 b | 13.3 b | 13.4 b |

## Accounts Payable | 36.1 m | 23.2 m | 52.9 m | 47 m | 47 m | 42.9 m | 29 m | 44.8 m | 61 m |

## Current Liabilities | 417.7 m | 502.5 m | 580.4 m | 769.2 m | 766.9 m | 603.6 m | 658.5 m | 1 b | 837 m |

## Additional Paid-in Capital | 2.5 b | 2.6 b | 2.7 b | 7.7 b | 7.6 b | 7.8 b | 7.9 b | 7.9 b | 8.1 b |

## Retained Earnings | 704.9 m | 882.7 m | 1.1 b | 1.3 b | 1.1 b | 1.3 b | 1.4 b | 1.7 b | 2 b |

## Total Equity | 2.9 b | 3.1 b | 3.5 b | 8.6 b | 8.3 b | 8.1 b | 8.2 b | 8.5 b | 8.9 b |

## Financial Leverage | 1.2 x | 1.2 x | 1.3 x | 1.5 x | 1.6 x | 1.6 x | 1.6 x | 1.6 x | 1.5 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 252.9 m | 656.9 m | 144.4 m | 399 m |

## Depreciation and Amortization | 28.7 m | 46.9 m | 166.6 m | 396 m |

## Accounts Receivable | (120 m) | (28 m) | (120 m) | (122 m) |

## Inventories | 126 k | (67 m) | (88 m) | (84 m) |

## Cash From Operating Activities | 497.3 m | 640.1 m | 675.2 m | 1.1 b |

## Purchases of PP&E | (29.3 m) | (136.7 m) | (286.3 m) | (333 m) |

## Cash From Investing Activities | (1 b) | (222.9 m) | (3.6 b) | (287 m) |

## Cash From Financing Activities | 71.6 m | 7.1 m | 3 b | (836 m) |

## Interest Paid | 2.8 m | 1.9 m | 41.4 m | 80 m |

## Income Taxes Paid | 76.2 m | 91.2 m | 123.2 m | 38 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 166.5 m | 177.7 m | 91.3 m | 170.2 m | (183.8 m) | 92.2 m | 114.9 m | 94.3 m | 170 m |

## Inventories | 144.9 m | 140 m | 174.5 m | 234.3 m | 236.5 m | 294 m | 329.8 m | 363.1 m | 396 m |

## Accounts Payable | 36.1 m | 23.2 m | 52.9 m | 47 m | 47 m | 42.9 m | 29 m | 44.8 m | 61 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 278.8 k |

## Financial Leverage | 1.5 x |

Source: 33 public H-1B filings from Alexion Pharmaceuticals

March 10, 2017

In a milestone year, global funding to private synthetic biology startups surpassed $1B in 2016. While biological engineering is not a new science, the surging reliability of genetic editing techniques and their increasingly creative applications have led to synthetic biology startups … Continued

December 12, 2016

Two top executives at Alexion Pharmaceuticals have left the company.
Alexion, a company that makes treatments for rare diseases, said on Monday that Chief Executive David Hallal had resigned, effective immediately, and named board member David Brennan as interim CEO.
The com…

October 14, 2016

Morgan Stanley has updated its annual list of secular growth stocks.
In a note published on Thursday, the firm highlighted 30 stocks that its analysts believe would thrive even if the global economy grows slower than they forecast.
To compile the list, Morgan Stanley first…

August 22, 2016

Stocks closed nearly flat in quiet trading Monday after drifting most of the day between gains and losses. Energy companies fell along with the price of oil while biotechnology and drug companies rose after Pfizer announced it was buying a cancer drug maker. Trading remained subdued, as it has..…

August 19, 2016

Another 17 companies lost more their half their value over the same period.

July 06, 2016

Here is what you need to know.
The British pound made a fresh 31-year low. Another day, another fresh 31-year low for the British pound. Sterling sank to 1.2798 in overnight action as traders continued to punish the currency amid the fallout from the Brexit vote. According t…